Shell Asset Management Co. Lowers Stock Position in Johnson & Johnson $JNJ

Shell Asset Management Co. decreased its position in Johnson & Johnson (NYSE:JNJ) by 47.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,296 shares of the company’s stock after selling 4,836 shares during the period. Shell Asset Management Co.’s holdings in Johnson & Johnson were worth $982,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank raised its position in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after buying an additional 692 shares in the last quarter. Wealth Group Ltd. boosted its holdings in Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after buying an additional 168 shares during the last quarter. Finally, Sendero Wealth Management LLC increased its stake in Johnson & Johnson by 4.2% during the 2nd quarter. Sendero Wealth Management LLC now owns 8,353 shares of the company’s stock worth $1,276,000 after buying an additional 337 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.5%

NYSE JNJ opened at $243.37 on Tuesday. The business’s fifty day simple moving average is $218.09 and its 200-day simple moving average is $197.35. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market cap of $586.51 billion, a PE ratio of 22.02, a P/E/G ratio of 2.36 and a beta of 0.35. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $246.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research report on Wednesday, January 28th. HSBC increased their price objective on Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. Argus increased their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Finally, Leerink Partners raised their price target on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.